Serina Therapeutics (SER) Proxy filing summary

Executive summary

• Annual meeting scheduled for December 13, 2024, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by December 12, 2024.

Voting matters and shareholder proposals

• Election of three Class I directors to serve until the 2027 annual meeting: Balkrishan "Simba" Gill, Remy Gross, and Steven Mintz.

• Ratification of Frazier & Deeter, LLC as independent registered public accountants for the fiscal year ending December 31, 2024.

• Approval of amendments to the 2024 Equity Incentive Plan, including increasing the share reserve to 2,675,000 and implementing an annual 5% evergreen increase from 2026 to 2034, with board discretion to limit increases.

• Proposal to modify the reversion of shares provisions in the equity plan.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director nominees and plan amendments.